Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine Combinations vs Sequential Cisplatin/Gemcitabine and Docetaxel in NSCLC
NCT00191490Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Antitumour activity as measured by response rate. Started Jul 2002; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00191490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191490.